These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 12090341)

  • 1. Update on the medical management of benign prostatic hyperplasia.
    Monga M
    Int Urol Nephrol; 2002; 33(1):67-8. PubMed ID: 12090341
    [No Abstract]   [Full Text] [Related]  

  • 2. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia.
    Andriole GL; Kirby R
    Eur Urol; 2003 Jul; 44(1):82-8. PubMed ID: 12814679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study.
    Yang XJ; Lecksell K; Short K; Gottesman J; Peterson L; Bannow J; Schellhammer PF; Fitch WP; Hodge GB; Parra R; Rouse S; Waldstreicher J; Epstein JI
    Urology; 1999 Apr; 53(4):696-700. PubMed ID: 10197843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia: an observational cohort study.
    Hong SJ; Ko WJ; Kim SI; Chung BH
    Eur Urol; 2003 Jul; 44(1):94-9; discussion 99-100. PubMed ID: 12814681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of finasteride in men with benign prostatic hyperplasia. 1992.
    Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS; Vaughan ED; Pappas F; Taylor A; Binkowitz B; Ng J;
    J Urol; 2002 Feb; 167(2 Pt 2):1102-7; discussion 1108. PubMed ID: 11905882
    [No Abstract]   [Full Text] [Related]  

  • 7. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens.
    Marks LS; Hess DL; Dorey FJ; Luz Macairan M; Cruz Santos PB; Tyler VE
    Urology; 2001 May; 57(5):999-1005. PubMed ID: 11337315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
    Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
    Andrology; 2017 Jul; 5(4):671-678. PubMed ID: 28453908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Finasteride, a steroid 5 alpha-reductase inhibitor, does not affect the oxidative metabolism of antipyrine.
    Winchell GA; Gregoire S; Taylor AM; Hegland J; Hunninghake DB
    J Clin Pharmacol; 1993 Oct; 33(10):967-70. PubMed ID: 7693768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy.
    Fwu CW; Eggers PW; Kirkali Z; McVary KT; Burrows PK; Kusek JW
    J Urol; 2014 Jun; 191(6):1828-34. PubMed ID: 24342143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug therapy of benign prostatic hyperplasia concentrates on early stages].
    Hofstetter A
    Fortschr Med; 1997 Feb; 115(5):8. PubMed ID: 9162723
    [No Abstract]   [Full Text] [Related]  

  • 12. [Factors determining treatment strategies for patients with benign prostatic hyperplasia. The DUO study].
    Fourcade RO; Picot MC; Gaudin AF; Texier N; Slama A
    Presse Med; 2007 May; 36(5 Pt 1):755-63. PubMed ID: 17329070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up.
    Lam JS; Romas NA; Lowe FC
    Urology; 2003 Feb; 61(2):354-8. PubMed ID: 12597947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of randomized clinical trials of finasteride.
    Roehrborn CG
    Urology; 1998 Apr; 51(4A Suppl):46-9. PubMed ID: 9586596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of benign prostatic hyperplasia with finasteride and doxazosin -- long-term studies support the combination].
    Hausmann R; Thalmann G; Reich O; Steif CG
    Aktuelle Urol; 2004 Sep; 35(5):339-42. PubMed ID: 15383991
    [No Abstract]   [Full Text] [Related]  

  • 16. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
    Habib FK; Ross M; Tate R; Chisholm GD
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
    Casabé A; Roehrborn CG; Da Pozzo LF; Zepeda S; Henderson RJ; Sorsaburu S; Henneges C; Wong DG; Viktrup L
    J Urol; 2014 Mar; 191(3):727-33. PubMed ID: 24096118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-term results of proscar (finasteride, MSD) treatment of patients with benign prostatic hyperplasia].
    Tkachuk VN; Al'-Shukri SKh; Kornienko VI; Kuz'min IV
    Urol Nefrol (Mosk); 1998; (4):37-9. PubMed ID: 9727320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of long-term administration of finasteride (MK-906), an inhibitor of 5 alpha-reductase, in patients with benign prostatic hyperplasia.
    Yoshida O; Oishi K; Okada Y; Mizutani Y; Itokawa Y; Tomoyoshi T; Okada K; Komatz Y; Matsuda T; Takeuchi H
    Hinyokika Kiyo; 1996 Apr; 42(4):323-31. PubMed ID: 8693970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia.
    Nichol MB; Knight TK; Wu J; Barron R; Penson DF
    J Urol; 2009 May; 181(5):2214-21; discussion 2221-2. PubMed ID: 19296986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.